In Brief: Gilead Sciences' Vistide
Executive Summary
Gilead Sciences' Vistide: Ophthalmic cytomegalovirus retinitis treatment NDA 20-638 will be considered by a March 15 joint meeting of FDA's Antiviral Drugs Advisory Committee and an ophthalmic drugs subcommittee of the Dermatologic & Ophthalmic Drugs Advisory Committee. The meeting will be held at the Holiday Inn in Gaithersburg, Md. beginning at 8:30 a.m...